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stroke, and hospitalization for worsening HF. Adverse 
events were observed in 39 patients (19.5 %). Patients with 
high SYNTAX scores (n = 100) showed worse prognoses 
than those with low scores (n = 100) (26.0 vs. 13.0 %, 
respectively, P = 0.021). In multivariate Cox-regression 
analysis, SYNTAX score ≥12 was significantly associated 
with MACE (hazard ratio: 1.99, 95 % confidence interval: 
1.02–3.97; P = 0.045). In patients with prior HF and CAD, 
high SYNTAX scores predicted a high incidence of MACE. 
These results suggest that the SYNTAX score might be a 
useful parameter for improving risk stratification in these 
patients.
Keywords Coronary artery disease · Heart failure · 
SYNTAX score · Prognosis
Abstract Although coronary artery disease (CAD) is com-
mon in patients with heart failure (HF), little is known 
about the prognostic significance of coronary lesion com-
plexity in patients with prior HF undergoing percutaneous 
coronary intervention (PCI). The aim of this study was to 
investigate whether the coronary Synergy between Percu-
taneous Coronary Intervention with TAXus and Cardiac 
Surgery (SYNTAX) score could improve risk stratification 
in HF patients with CAD. Two hundred patients (mean age 
73 ± 11 years, left ventricular ejection fraction 49 ± 15 %) 
with prior HF who underwent PCI were divided into two 
groups stratified by SYNTAX score (median value 12) 
and tracked prospectively for 1 year. The study endpoint 
was the composite of major adverse cardiovascular events 
(MACE), including all-cause death, myocardial infarction, 
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Introduction
Heart failure (HF) is a serious healthcare problem in today’s 
aging society. Despite significant advances in the treat-
ment of chronic HF, the disease tends to follow a progres-
sive course with high mortality and morbidity rates [1–3]. 
Patients with HF are at significant risk for recurrent cardio-
vascular events such as death, myocardial infarction (MI), 
stroke, and hospitalization for worsening HF. Therefore, 
the secondary prevention of cardiovascular events is invalu-
able for improving the prognostic outlook of HF patients. A 
novel risk stratification system would provide critical infor-
mation that could result in more aggressive therapy and lead 
to improved patient survival. Coronary artery disease (CAD) 
has contributed to the increased prevalence of HF and is 
associated with cardiovascular events in patients with HF 
[4–7]. The Synergy between Percutaneous Coronary Inter-
vention with TAXus and Cardiac Surgery (SYNTAX) score, 
a measure of coronary lesion complexity, has been proposed 
for use in the risk stratification of patients with untreated left 
main trunk or 3-vessel CAD [8, 9]. However, the prognostic 
significance of the SYNTAX score for risk stratification in 
HF patients is poorly understood. We hypothesized that the 
SYNTAX score would predict adverse cardiovascular events 
in patients with HF. The aim of this study was to investigate 
whether the coronary SYNTAX score could improve risk 
stratification in HF patients with CAD.
Materials and methods
Study population
This cohort study retrospectively reviewed data available 
from the SHINANO registry (Shinshu prospective multi-
center study of elderly patients with CAD undergoing per-
cutaneous coronary intervention (PCI)) obtained between 
August 2012 and July 2013. A detailed summary of the 
methods and design of this registry has been published pre-
viously [10]. Briefly, the SHINANO registry is a prospec-
tive, multi-center observational registry of patients with any 
CAD diagnosis, including stable angina, ST-segment eleva-
tion MI, non-ST-segment elevation MI, and unstable angina, 
undergoing PCI at 16 collaborating hospitals located in 
the Nagano prefecture, Japan. As it is an all-comer reg-
istry, there are no exclusion criteria. The institutional 
review board approved the protocol, which was registered 
at the University Hospital Medical Information Network 
(UMIN000010070), and informed consent was obtained 
from each patient before enrollment. This study was per-
formed in accordance with the Declaration of Helsinki.
Among the 1923 patients registered in the SHINANO 
registry, we screened 254 patients with a history of HF. 
After excluding patients with a history of coronary artery 
bypass grafting (CABG), as well as those with missing 
data concerning left ventricular ejection fraction (LVEF) 
or no SYNTAX score, we enrolled 200 patients with prior 
HF into the final study. All patients were prospectively fol-
lowed for 12 months from the date of the PCI procedure. 
The study endpoint was the composite of major adverse 
cardiovascular events (MACE), including all-cause death, 
MI, stroke, and hospitalization for worsening HF using a 
time-to-first-event analysis.
Study definitions
MI was diagnosed according to the American College 
of Cardiology/American Heart Association (ACC/AHA) 
guidelines [11]. Stroke was defined as an ischemic cerebro-
vascular event that persisted for ≥24 h and was diagnosed 
by a neurologist [12]. Prior HF was based on a previous 
diagnosis of HF according to the Framingham criteria [13] 
or a history of hospitalization for worsening HF. Body 
mass index was defined as weight in kilograms divided by 
the square of height in meters. Patients with systolic blood 
pressure >140 mmHg and/or diastolic pressure >90 mmHg 
and those taking anti-hypertensive agents were considered 
to have hypertension. Dyslipidemia was defined as a serum 
total cholesterol concentration ≥220 mg/dL, low-density 
lipoprotein cholesterol ≥140 mg/dL, or the need for treat-
ment with lipid-lowering agents. Diabetes mellitus was 
defined as hemoglobin (Hb) A1c ≥6.5 %, random plasma 
glucose ≥220 mg/dL, or a clinical history of oral hypogly-
cemic agent and/or insulin use. Patients were considered 
smokers if they were current smokers. CAD was defined 
as >50 % stenosis in a coronary vessel on angiography, 
history of CABG or PCI, or history of MI. Multi-vessel 
disease was defined as the presence of a ≥75 % lesion in 
≥2 major coronary arteries. The SYNTAX score was cal-
culated as previously described [9]. Complete revasculari-
zation was considered to have occurred when all stenotic 
main vessels and all side branches greater than 2 mm in 
diameter were revascularized [14]. Estimated glomerular 
filtration rate (eGFR) was calculated using the Modifica-
tion of Diet and Renal Disease equation with coefficients 
modified for Japanese patients [15]. Chronic kidney disease 
was defined as an eGFR <60 ml/min/1.73 m2. LVEF was 
calculated using the Teichholz method in patients without 
regional wall motion abnormality or the biplane Simpson’s 
method in those with regional wall motion abnormality [16, 
17]. All PCI procedures and selection of medical treatments 
after PCI were at the discretion of the treating physician.
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Statistical analysis
Continuous variables were summarized as mean ± stand-
ard deviation if normally distributed or as median and inter-
quartile range otherwise. Normality was evaluated using 
the Shapiro–Wilk W test. Comparisons of baseline cat-
egorical data between the two groups were analyzed using 
two-sided Chi-squared tests, whereas differences between 
continuous variables were analyzed using an unpaired t test 
or the Mann–Whitney U test. The optimal cutoff value for 
MACE prediction was chosen as the value that maximized 
sensitivity and specificity on the receiver operating char-
acteristics (ROC) curve. Kaplan–Meier curves were con-
structed from the date of the PCI procedure to the MACE 
and were compared using the log-rank test. Cox propor-
tional hazards regression analysis was performed to iden-
tify the MACE predictors, using variables that included 
clinical characteristics and risk factors. Multivariate analy-
sis was performed using all variables with a P value <0.1 
in the univariate analysis. A P value <0.05 was considered 
to indicate statistical significance. All analyses were per-




All of the patients initially enrolled in the study com-
pleted the follow-up. Using the median value of the SYN-
TAX score (12), patients were divided into a high-SYN-
TAX score group (n = 100) and a low-SYNTAX group 
(n = 100) (Fig. 1). During the 12-month follow-up period, 
adverse events were observed in 39 patients (19.5 %) and 
included deaths (n = 25), MIs (n = 5), strokes (n = 5), and 
hospitalizations for HF (n = 18) (Table 1). The baseline 
clinical characteristics are listed in Table 2. Patients with 
high SYNTAX scores did not differ from those with low 
scores with respect to age, sex, the prevalence of hyper-
tension, dyslipidemia, diabetes mellitus, atrial fibrilla-
tion, chronic kidney disease, prior stroke, hemodialysis, 
or peripheral artery disease. Patients with high SYNTAX 
scores had significantly more severe HF symptoms, as esti-
mated by New York Heart Association (NYHA) functional 
class, compared with those with low SYNTAX scores. As 
expected, the prevalence of multi-vessel disease was signif-
icantly higher in patients with high SYNTAX scores com-
pared with those with low scores. Complete revasculariza-
tion was significantly rarer in patients with high SYNTAX 
scores. The use of angiotensin-converting enzyme inhibi-
tors, angiotensin receptor blockers, beta-blockers, and 
statins was similar between the two groups. Hb, low-den-
sity lipoprotein cholesterol, eGFR, and HbA1c levels were 
similar between the two groups, whereas levels of brain 
natriuretic peptide tended to be higher in patients with high 
SYNTAX scores than in those with low scores. LVEF was Fig. 1  Study design. CABG coronary artery bypass graft
Table 1  Clinical outcomes
Values are number (%)
MACE major adverse cardiac events (including all-cause death, myocardial infarction, stroke, and hospi-
talization for heart failure)
Overall (n = 200) Low-SYNTAX group 
(<12) (n = 100)
High-SYNTAX group 
(≥12) (n = 100)
P value
MACE, n (%) 39 (19.5) 13 (13.0) 26 (26.0) 0.021
All-cause death, n (%) 25 (12.5) 4 (4.0) 21 (21.0) <0.001
Cardiac death, n (%) 13 (6.5) 1 (1.0) 12 (12.0) 0.001
Myocardial infarction, 
n (%)
5 (2.5) 3 (3.0) 2 (2.0) 0.58
Stroke, n (%) 5 (2.5) 2 (2.0) 3 (3.0) 0.60
Hospitalization for heart 
failure, n (%)
18 (9.0) 7 (7.0) 11 (11.0) 0.24
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Table 2  Baseline characteristics 





(<12) (n = 100)
High-SYNTAX group 
(≥12) (n = 100)
P value
Age 73 ± 11 73 ± 11 74 ± 11 0.58
Female sex, n (%) 47 (23.4) 18 (18.0) 29 (29.0) 0.067
Body mass index (kg/m2) 22.6 ± 4.1 23.1 ± 3.9 22.2 ± 4.3 0.14
Ischemic etiology (%) 66.7 58.3 75.6 0.001
NYHA functional class ≥III, 
n (%)
60 (30.0) 23 (23.0) 37 (37.0) 0.031
Comorbidities
 Hypertension, n (%) 157 (78.1) 78 (78.0) 79 (79.0) 0.86
 Dyslipidemia, n (%) 127 (63.2) 62 (62.0) 65 (65.0) 0.66
 Diabetes mellitus, n (%) 76 (37.8) 40 (40.0) 36 (36.0) 0.56
 Current smoker, n (%) 25 (12.4) 12 (12.0) 13 (13.0) 0.87
 Atrial fibrillation, n (%) 56 (28.0) 34 (34.0) 22 (22.0) 0.059
 Chronic kidney disease, n 
(%)
132 (66.0) 72 (72.0) 60 (60.0) 0.10
 Prior stroke, n (%) 27 (13.5) 12 (12.0) 15 (15.0) 0.68
 Hemodialysis, n (%) 22 (11.0) 15 (15.0) 7 (7.0) 0.11
 Peripheral artery disease, 
n (%)
37 (18.5) 17 (17.0) 20 (20.0) 0.72
Angiographic data
 Target coronary lesion
  Right coronary artery, n 
(%)
72 (36.0) 41 (41.0) 31 (31.0) 0.19
  Left anterior descending 
artery, n (%)
92 (46.0) 40 (40.0) 52 (52.0) 0.12
  Left circumflex artery, 
n (%)
31 (15.5) 18 (18.0) 13 (13.0) 0.44
  Left main trunk, n (%) 5 (2.5) 1 (1.0) 4 (4.0) 0.37
  De novo lesion, n (%) 170 (67.5) 83 (83.0) 87 (87.0) 0.55
  Only POBA 41 (20.5) 21 (21.0) 20 (20.0) 0.86
 Type of implanted stent
  Drug-eluting stent, n (%) 135 (67.5) 69 (69.0) 66 (66.0) 0.76
  Bare metal stent, n (%) 24 (12.0) 10 (10.0) 14 (14.0) 0.52
  Calcification lesion, n (%) 73 (36.5) 32 (32.0) 41 (41.0) 0.24
  Bifurcation lesion, n (%) 58 (29.0) 20 (20.0) 38 (38.0) 0.008
  Ostial lesion, n (%) 15 (7.5) 5 (5.0) 10 (10.0) 0.28
  Multi-vessel, n (%) 83 (41.3) 23 (23.0) 60 (60.0) <0.001
  SYNTAX score 13.7 ± 9.5 6.4 ± 2.4 21.1 ± 8.1 <0.001
  Complete revasculariza-
tion, n (%)
123 (61.5) 72 (72.0) 51 (51.0) 0.001
  Acute coronary syndrome, 
n (%)
61 (30.3) 27 (27.0) 34 (34.0) 0.28
  STEMI on admission, n 
(%)
38 (19.0) 10 (10.0) 28 (28.0) 0.002
  Killip class IV on admis-
sion, n (%)
11 (5.5) 1 (1.0) 10 (10.0) 0.010
 Medications at discharge
  Aspirin, n (%) 187 (93.5) 96 (96.0) 91 (91.0) 0.21
  Thienopyridines, n (%) 167 (83.5) 89 (89.0) 78 (78.0) 0.049
  Warfarin, n (%) 56 (28.0) 33 (33.0) 23 (23.0) 0.16
  ACE-inhibitor/ARB, n 
(%)
157 (78.1) 81 (81.0) 76 (76.0) 0.79
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significantly lower in patients with high SYNTAX scores 
than in those with low scores.
Predictors of MACE
In the Kaplan–Meier analysis, patients with high SYNTAX 
scores (≥12) showed worse prognoses than those with 
low SYNTAX scores (<12) (26.0 vs. 13.0 %, respectively, 
P = 0.021) (Fig. 2). After multivariate Cox proportional 
hazards analysis, which included age, sex, and all vari-
ables with P < 0.1 in the univariate analysis, a high SYN-
TAX score predicted a poor prognosis (Table 3). Based on 
the SYNTAX scores in our study, the area under the ROC 
curve (AUC) was 0.63 (Fig. 3) and the optimal cutoff point 
for predicting adverse events was a SYNTAX score of 11.8 
(sensitivity 68.0 %, specificity 56.0 %).
Discussion
To the best of our knowledge, this is the first report to 
investigate the prognostic significance of the SYNTAX 
score for predicting cardiovascular events in patients with 
prior HF undergoing PCI. We demonstrated that a high 
SYNTAX score was an independent predictor of MACE in 
this patient population.
The SYNTAX score established itself as an impor-
tant tool in the SYNTAX trial, which pioneered the Heart 
Team approach, in which the interventional cardiologist 
and cardiac surgeon determined the optimal revasculariza-
tion modality for patients with untreated left main trunk 
or 3-vessel CAD [9]. SYNTAX is a very convenient scor-
ing system for assessing the coronary lesion complexity in 
patients with CAD. Previous studies have demonstrated that 
a higher score is an independent marker of poor cardiovas-
cular prognosis in patients with CAD [18, 19]. Importantly, 
risk stratification using the SYNTAX score has been vali-
dated in patients with CAD [20, 21]; however, there have 
been no studies using the SYNTAX score for risk stratifica-
tion in HF patients undergoing PCI. In our study, we dem-
onstrated that the SYNTAX score had predictive value for 
Table 2  continued Overall 
(n = 200)
Low-SYNTAX group 
(<12) (n = 100)
High-SYNTAX group 
(≥12) (n = 100)
P value
  Beta-blocker, n (%) 118 (58.7) 57 (57.0) 61 (61.0) 0.44
  Statin, n (%) 134 (66.7) 61 (61.0) 73 (73.0) 0.053
  Insulin user, n (%) 18 (9.0) 12 (12.0) 6 (6.0) 0.14
 Laboratory data
  Hemoglobin (g/dL) 12.7 ± 3.0 12.7 ± 2.0 12.8 ± 3.9 0.84
  LDL-C (mg/dL) 99.3 ± 33.8 96.0 ± 28.4 102.8 ± 38.6 0.17
  eGFR (mL/min/1.73 m2 
surface area)
50.3 ± 23.9 49.2 ± 22.5 51.3 ± 25.4 0.53
  Hemoglobin A1c (%) 6.1 ± 1.0 6.1 ± 0.9 6.1 ± 1.0 0.86
  BNP (pg/mL) 304 [133, 733] 241 [123, 456] 427 [137, 1021] 0.067
  LV ejection fraction (%) 49.4 ± 14.7 52.6 ± 15.7 46.2 ± 13.0 0.002
Values are number (%), mean ± standard deviation, or median [25th, 75th percentiles]
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, BNP B-type natriuretic peptide, 
eGFR estimated glomerular filtration rate, LDL low-density lipoprotein cholesterol, LV left ventricular, 
MACE major adverse cardiac events (including all-cause death, myocardial infarction, stroke, and hospitali-
zation for heart failure), POBA plain old balloon angioplasty
Fig. 2  Kaplan–Meier curves for MACE according to SYNTAX 
score. MACE major adverse cardiac events (including all-cause death, 
myocardial infarction, stroke, and hospitalization for HF)
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MACE in prior HF patients with CAD undergoing PCI. This 
result was consistent with previous reports on the prognostic 
value of the SYNTAX score in patients with acute MI [22].
We demonstrated that the AUC of the SYNTAX score 
for predicting adverse events was 0.63. This value was 
similar to that reported by a previous study which eval-
uated the value of the SYNTAX score for predicting 
12-month clinical outcomes in acute MI (AUC: 0.65) 
[23]. Furthermore, the AUC of the SYNTAX score for 
predicting 12-month adverse events was 0.60 in the 
SHNINO registry study which included prior HF and 
non-HF patients. This AUC also approximates that of 
the SYNTAX score for predicting 5-year adverse events 
which was reported as 0.61 in the SYNTAX trial [18]. It 
remains unclear whether the SYNTAX score is a more 
useful parameter in patients with more severe cardiovas-
cular diseases, such as HF and MI, than in those with lone 
CAD. A high SYNTAX score was also an independent 
predictor of MACE after multivariate analysis. Although 
the mechanism of the association between the SYNTAX 
score and MACE might be multifactorial, previous reports 
demonstrated that a higher SYNTAX score was associated 
with complex CAD and a higher prevalence of diabetes 
mellitus and peripheral artery disease, suggesting that the 
SYNTAX score may be related to advanced coronary and 
systemic atherosclerosis [24, 25].
Table 3  Cox Proportional 
Hazards Analyses of MACE
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, BNP B-type natriuretic peptide, CI 
confidence interval, eGFR estimated glomerular filtration rate, HR hazard ratio, LV left ventricular, MACE 
major adverse cardiac events (including all-cause death, myocardial infarction, stroke, and hospitalization 
for heart failure)
* Adjusted for age, sex, NYHA functional class ≥III, and SYNTAX score ≥12
Univariate Multivariate*
HR (95 % CI) P value HR (95 % CI) P value
Age 1.03 (1.02–1.10) 0.087 1.02 (0.98–1.05) 0.36
Female sex 1.55 (0.78–3.06) 0.21 1.25 (0.62–2.52) 0.53
NYHA functional class ≥ III 1.99 (1.06–3.75) 0.033 1.87 (0.98–3.56) 0.057
Diabetes mellitus 1.66 (0.89–3.11) 0.11
Atrial fibrillation 1.56 (0.81–3.00) 0.18
Chronic kidney disease 1.44 (0.63–3.10) 0.35
Hemodialysis 0.19 (0.025–1.35) 0.17
Prior stroke 0.77 (0.27–2.16) 0.16
Peripheral artery disease 1.24 (0.57–2.70) 0.59
Multi-vessel disease 1.14 (0.75–1.74) 0.53
SYNTAX score ≥12 2.14 (1.10–4.17) 0.025 1.99 (1.02–3.90) 0.045
Aspirin 0.81 (0.43–1.55) 0.53
Thienopyridines 0.79 (0.42–1.48) 0.46
ACE-inhibitor/ARB 1.16 (0.60–2.24) 0.65
Beta-blocker 0.76 (0.50–1.45) 0.41
Insulin 1.55 (0.60–4.00) 0.36
Hemoglobin 0.97 (0.86–1.09) 0.58
eGFR 0.99 (0.96–1.03) 0.82
BNP 1.00 (1.00–1.01) 0.75
LV ejection fraction 0.98 (0.96–1.00) 0.17
Fig. 3  Receiver-operating characteristic (ROC) curve for predicting 
adverse events. The area under the ROC curve (AUC) for the SYN-
TAX score was 0.63, with an optimal ROC cutoff point of 11.8. CI 
confidence interval
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Clinical implications
Our study demonstrated that the SYNTAX score is useful 
for assessing the prognosis of patients with a prior diag-
nosis of HF undergoing PCI. Given that prior HF patients 
have a high risk of recurrent cardiovascular events such as 
sudden death and hospitalization for worsening HF, we rec-
ommend that calculation of the SYNTAX score should be 
performed in prior HF patients with CAD to allow for pre-
cise risk stratification for MACE.
Study limitations
The major limitation of our study is that it was an obser-
vational study with a relatively small number of subjects 
and, therefore, the possibility of selection bias and unmeas-
ured confounding factors might not have been completely 
excluded. Thus, our results should be interpreted cautiously 
until verified by large-scale multi-center studies. However, 
our study is the first to report on the utility of the SYNTAX 
score in prior HF patients with CAD undergoing PCI. Sec-
ond, our definition of HF relied on an investigator diagnosis 
based on the Framingham criteria, rather than a requirement 
to fulfill all of the criteria recommended in the guidelines. 
Third, we analyzed the predictive value of SYNTAX score 
using an individual cutoff point and, therefore, further stud-
ies are needed to determine the optimal cutoff points in 
this patient population. Fourth, we did not assess biomark-
ers which are known predictors of cardiovascular events, 
despite the fact that certain novel biomarkers are associated 
with a higher SYNTAX score [26, 27]. Fifth, only prior HF 
patients diagnosed with CAD were included in this study 
and, therefore, our results may not apply to all HF patients. 
Despite these limitations, our findings provide new insight 
into the risk stratification for cardiovascular events in prior 
HF patients undergoing PCI. Furthermore, since our study 
was based on observational registry data from patients with 
CAD, we consider that our results represent a real-world 
unselected population of prior HF patients undergoing PCI.
Conclusions
In prior HF patients with CAD, high SYNTAX scores pre-
dicted a high incidence of MACE. The SYNTAX score 
might be a useful parameter for improving risk stratifica-
tion in these patients.
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